Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 428619, 7 pages
http://dx.doi.org/10.1155/2014/428619
Research Article

A Novel Stent Coated with Antibodies to Endoglin Inhibits Neointimal Formation of Porcine Coronary Arteries

1The Key Laboratory of Remodeling-Related Cardiovascular Diseases, Department of Cardiology, Anzhen Hospital Affiliated to Capital Medical University, Beijing 100029, China
2Department of Radiology, China-Japan Friendship Hospital, Beijing 100029, China
3Southern Hospital Affiliated to Southern Medical University, Guangzhou 510515, China
4Department of Cardiology, Binzhou Central Hospital, Binzhou 251700, China
5Laboratory of the Animal Center, Academy of Military Medical Sciences, No. 27 Taiping Road, Haidian District, Beijing 100850, China
6School of Medicine, University of California, San Diego, CA 92103, USA

Received 16 January 2014; Accepted 5 April 2014; Published 4 May 2014

Academic Editor: Jörn Tongers

Copyright © 2014 Song Cui et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. F. Lüscher, J. Steffel, F. R. Eberli et al., “Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications,” Circulation, vol. 115, no. 8, pp. 1051–1058, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. L. Slavin, A. Chhabra, and J. M. Tobis, “Drug-eluting stents: preventing restenosis,” Cardiology in Review, vol. 15, no. 1, pp. 1–12, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Kraitzer, Y. Kloog, and M. Zilberman, “Approaches for prevention of restenosis,” Journal of Biomedical Materials Research B—Applied Biomaterials, vol. 85, no. 2, pp. 583–603, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. N. Kipshidze, G. Dangas, M. Tsapenko et al., “Role of the endothelium in modulating neointimal formation: vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions,” Journal of the American College of Cardiology, vol. 44, no. 4, pp. 733–739, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. N. Werner, S. Junk, U. Laufs et al., “Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury,” Circulation Research, vol. 93, no. 2, pp. e17–24, 2003. View at Google Scholar · View at Scopus
  6. D. H. Walter, K. Rittig, F. H. Bahlmann et al., “Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells,” Circulation, vol. 105, no. 25, pp. 3017–3024, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. P. W. Serruys, M. J. B. Kutryk, and A. T. L. Ong, “Coronary-artery stents,” The New England Journal of Medicine, vol. 354, no. 5, pp. 483–495, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Nakazawa, A. V. Finn, M. Joner et al., “Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study,” Circulation, vol. 118, no. 11, pp. 1138–1145, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. A. V. Finn, G. Nakazawa, M. Joner et al., “Vascular responses to drug eluting stents: importance of delayed healing,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 7, pp. 1500–1510, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Shirota, H. Yasui, H. Shimokawa, and T. Matsuda, “Fabrication of endothelial progenitor cell (EPC)-seeded intravascular stent devices and in vitro endothelialization on hybrid vascular tissue,” Biomaterials, vol. 24, no. 13, pp. 2295–2302, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Nakazawa, J. F. Granada, C. L. Alviar et al., “Anti-CD34 antibodies immobilized on the surface of sirolimus-eluting stents enhance stent endothelialization,” JACC: Cardiovascular Interventions, vol. 3, no. 1, pp. 68–75, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Aoki, P. W. Serruys, H. van Beusekom et al., “Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First in Man) registry,” Journal of the American College of Cardiology, vol. 45, no. 10, pp. 1574–1579, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Bellon, A. Corbi, P. Lastres et al., “Identification and expression of two forms of the human transforming growth factor-β-binding protein endoglin with distinct cytoplasmic regions,” European Journal of Immunology, vol. 23, no. 9, pp. 2340–2345, 1993. View at Google Scholar · View at Scopus
  14. H. Yamashita, H. Ichijo, S. Grimsby, A. Morén, P. Ten Dijke, and K. Miyazono, “Endoglin forms a heteromeric complex with the signaling receptors for transforming growth factor-β,” Journal of Biological Chemistry, vol. 269, no. 3, pp. 1995–2001, 1994. View at Google Scholar · View at Scopus
  15. S. Cheifetz, T. Bellon, C. Cales et al., “Endoglin is a component of the transforming growth factor-β receptor system in human endothelial cells,” Journal of Biological Chemistry, vol. 267, no. 27, pp. 19027–19030, 1992. View at Google Scholar · View at Scopus
  16. S. St.-Jacques, U. Cymerman, N. Pece, and M. Letarte, “Molecular characterization and in situ localization of murine endoglin reveal that it is a transforming growth factor-β binding protein of endothelial and stromal cells,” Endocrinology, vol. 134, no. 6, pp. 2645–2657, 1994. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Gougos, S. St.-Jacques, A. Greaves et al., “Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts,” International Immunology, vol. 4, no. 1, pp. 83–92, 1992. View at Google Scholar · View at Scopus
  18. R. Qu, M. M. Silver, and M. Letarte, “Distribution of endoglin in early human development reveals high levels on endocardial cushion tissue mesenchyme during valve formation,” Cell and Tissue Research, vol. 292, no. 2, pp. 333–343, 1998. View at Publisher · View at Google Scholar · View at Scopus
  19. E. Fonsatti, H. J. M. Nicolay, M. Altomonte, A. Covre, and M. Maio, “Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours,” Cardiovascular Research, vol. 86, no. 1, pp. 12–19, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. H. H. Li, V. Kedar, C. Zhang et al., “Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex,” Journal of Clinical Investigation, vol. 114, no. 8, pp. 1058–1071, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. X. Ma, B. Hibbert, B. Dhaliwal et al., “Delayed re-endothelialization with rapamycin-coated stents is rescued by the addition of a glycogen synthase kinase-3 inhibitor,” Cardiovascular Research, vol. 86, no. 2, pp. 338–345, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Steigerwald, S. Merl, A. Kastrati et al., “The pre-clinical assessment of rapamycin-eluting, durable polymer-free stent coating concepts,” Biomaterials, vol. 30, no. 4, pp. 632–637, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. R. S. Schwartz, K. C. Huber, J. G. Murphy et al., “Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model,” Journal of the American College of Cardiology, vol. 19, no. 2, pp. 267–274, 1992. View at Google Scholar · View at Scopus
  24. J. H. Young, H. J. Myung, R. L. Sang et al., “Anti-inflammatory effect of abciximab-coated stent in a porcine coronary restenosis model,” Journal of Korean Medical Science, vol. 22, no. 5, pp. 802–809, 2007. View at Google Scholar · View at Scopus
  25. R. Blindt, F. Vogt, I. Astafieva et al., “A novel drug-eluting stent coated with an integrin-binding cyclic arg-gly-asp peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cells,” Journal of the American College of Cardiology, vol. 47, no. 9, pp. 1786–1795, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. O. Soehnlein, S. Wantha, S. Simsekyilmaz et al., “Neutrophil-derived cathelicidin protects from neointimal hyperplasia,” Science Translational Medicine, vol. 3, no. 103, Article ID 103ra98, 2011. View at Google Scholar · View at Scopus
  27. M. E. Pfisterer, “Late stent thrombosis after drug-eluting stent implantation for acute myocardial infarction a new red flag is raised,” Circulation, vol. 118, no. 11, pp. 1117–1119, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. G. Ertaş, H. M. van Beusekom, and W. J. van der Giessen, “Late stent thrombosis, endothelialisation and drug-eluting stents,” The Netherlands Heart Journal, vol. 17, no. 4, pp. 177–180, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. J. H. Houtgraaf and H. J. Duckers, “Endothelial progenitor cell (EPC) capture to aid vascular repair following coronary stenting: a new frontier in stent technology?” EuroIntervention C, vol. 4, pp. 67–71, 2008. View at Google Scholar · View at Scopus
  30. E. Chong, K. K. Poh, S. Liang et al., “Two-year clinical registry follow-up of endothelial progenitor cell capture stent versus sirolimus-eluting bioabsorbable polymer coated stent versus bare metal stents in patients undergoing primary percutaneous coronary intervention for ST elevation myocardial infarction,” Journal of Interventional Cardiology, vol. 23, no. 2, pp. 101–108, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. N. A. Dallas, S. Samuel, L. Xia et al., “Endoglin (CD105): a marker of tumor vasculature and potential target for therapy,” Clinical Cancer Research, vol. 14, no. 7, pp. 1931–1937, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. P. Lastres, A. Letamendía, H. Zhang et al., “Endoglin modulates cellular responses to TGF-β1,” Journal of Cell Biology, vol. 133, no. 5, pp. 1109–1121, 1996. View at Publisher · View at Google Scholar · View at Scopus
  33. F. Lebrin, M. Deckers, P. Bertolino, and P. Ten Dijke, “TGF-β receptor function in the endothelium,” Cardiovascular Research, vol. 65, no. 3, pp. 599–608, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. E. A. Liehn, A. Schober, and C. Weber, “Blockade of keratinocyte-derived chemokine inhibits endothelial recovery and enhances plaque formation after arterial injury in apoE-deficient mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 10, pp. 1891–1896, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Banerjee, E. Brilakis, S. Zhang et al., “Endothelial progenitor cell mobilization after percutaneous coronary intervention,” Atherosclerosis, vol. 189, no. 1, pp. 70–75, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Shintani, T. Murohara, H. Ikeda et al., “Mobilization of endothelial progenitor cells in patients with acute myocardial infarction,” Circulation, vol. 103, no. 23, pp. 2776–2779, 2001. View at Google Scholar · View at Scopus
  37. N. Werner, J. Priller, U. Laufs et al., “Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 10, pp. 1567–1572, 2002. View at Publisher · View at Google Scholar · View at Scopus